Alethio Therapeutics has raised $90 million (£67 million) to take a new essential thrombocythemia (ET) antibody, ATX-011, into its first human studies. The Oxford, UK, company announced the oversubscribed Series A financing on November 5, 2026. It is real momentum for ET research. It is not a new treatment option. Alethio describes ATX-011 as still in […]